Additional data from APPRAISE ATP trial reinforce modular therapy approach
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Around 7% of the Indian population suffers from IBS
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
A significant proportion of healthcare professionals still tend to favor branded drugs
Subscribe To Our Newsletter & Stay Updated